-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NNOZgk8dtssWcvW9bbnf8LMCJ6/tCBNY+9HhaubqXjFgiz5g+JnLaujEE4iDWNkY rKA/lKwwp4T+opoXLQs5Pw== 0000069499-03-000009.txt : 20030211 0000069499-03-000009.hdr.sgml : 20030211 20030211161517 ACCESSION NUMBER: 0000069499-03-000009 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030207 FILED AS OF DATE: 20030211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MYLAN LABORATORIES INC CENTRAL INDEX KEY: 0000069499 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 251211621 STATE OF INCORPORATION: PA FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09114 FILM NUMBER: 03550409 BUSINESS ADDRESS: STREET 1: 130 SEVENTH ST STREET 2: 1030 CENTURY BLDG CITY: PITTSBURGH STATE: PA ZIP: 15222 BUSINESS PHONE: 4122320100 MAIL ADDRESS: STREET 1: 1030 CENTURY BUILDING STREET 2: 130 SEVENTH STREET CITY: PITTSBURGH STATE: PA ZIP: 15222 FORMER COMPANY: FORMER CONFORMED NAME: FRM CORP DATE OF NAME CHANGE: 19711003 REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: GAISFORD JOHN C DR CENTRAL INDEX KEY: 0001114100 RELATIONSHIP: DIRECTOR FILING VALUES: FORM TYPE: 4 BUSINESS ADDRESS: STREET 1: SUITE 340 STREET 2: MELLON PAVILION CITY: PITTSBURGH STATE: PA ZIP: 15224 BUSINESS PHONE: 4126815266 MAIL ADDRESS: STREET 1: SUITE 340 MELLON PAVILION CITY: PITTSBURGH STATE: PA ZIP: 15224 4 1 gaisford.htm JOHN C. GAISFORD FORM 4 Form 4
FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility
Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB Number:          3235-0287
Expires:           January 31, 2005
[_] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Respones)
Estimated average burden
hours per response.                               0.5
1. Name and Address of Reporting Person*
Gaisford John C.
2. Issuer Name and Ticker or Trading Symbol
Mylan Laboratories Inc. (MYL)

6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
[X]    Director                                   [_]   10% Owner
[_]    Officer (give title below)             [_]   Other (specify below)
                                    


(Last)             (First)            (Middle)

910 Waldheim Road West
3. I.R.S. Identification Number of Reporting Person, if an entity
(voluntary)

4. Statement for Month/Day/Year
February 7, 2003
(Street)
Pittsburgh, PA 15215
5. If Amendment, Date of Original (Month/Day/Year)
7. Individual or Joint/Group Filing
(Check Applicable Line)
[X]  Form filed by One Reporting Person
[_] Form filed by More than One Reporting Person
(City)             (State)             (Zip) Table I — Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security
(Instr. 3)

2. Trans-
action
Date
(mm/dd/yy)

2A.
Deemed
Execution
Date, if
any
(mm/dd/yy)
3. Transaction
Code (Instr. 8)
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction
(Instr. 3 and 4)
6. Owner-
ship Form:
Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A)
or
(D)
Price
Mylan Laboratories Inc. Common Stock 02/07/03   M   22,500 A $11.8333 36,750 D  
Mylan Laboratories Inc. Common Stock 02/07/03   S   22,500 D $26.1848 14,250 D  
Mylan Laboratories Inc. Common Stock               601 I Held by wife in IRA ( Personal Account)
                     
                     
                     
                     
                     

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.          Mylan Laboratories Inc. Incurred a 3 for 2 stock split on January 27, 2003. Shares reported are on a post-split basis.
* If the form is filed by more than one reporting person, see Instructions 4(b)(v).

 
Persons who respond to the collection of information contained
in this form are not required to respond unless the form displays
a currently vaild OMB control Number.
(Over)
SEC 1474 (9-02)



FORM 4 (continued)
Table II —Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
 
1.Title of Derivative Security
(Instr.3)
2.  Conversion
or Exercise
Price of
Derivative
Security
3.  Transaction
Date
(Month/
Day/
Year)
3A.
Deemed
Execution
Date if
any
(Month/
Day/
Year)
4. Transaction Code  Instr. 8) 5. Number of Derivative
Securities  Acquired (A) or
Disposed of  (D)  (Instr. 3, 4 and 5)
6. Date Exercisable
and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying
Securities
(Instr. 3 and 4)
8. Price of
Derivative
Security
(Instr. 5)

9.Number of
Deriv-
ative
Secur-
ities
Bene-
ficially
Owned
Follow-
ing
Reported
Trans-
action(s)

(Instr. 4)

10. Owner-
ship
Form of
Deriv-
ative
Security:
Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of
Indirect
Benefi-
cial
Owner-
ship
(Instr. 4)
Code V (A) (D) Date
Exercisable
Expiration
Date
Title Amount or
Number
of Shares
Non-Qualified Stock Option (right to buy) $11.8333 2/7/2003   M     22,500 5/8/1998 5/8/2008 Common Stock 22,500   111,750 D  
                               
                               
Explanation of Responses:      Mylan Laboratories Inc. Incurred a 3 for 2 stock split on January 27, 2003. Shares reported are on a post-split basis.
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
/s/  John C. Gaisford
**Signature of Reporting Person
2/11/2003  
Date
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number.
Page 2


-----END PRIVACY-ENHANCED MESSAGE-----